Opinion/decision on a Paediatric investigation plan (PIP): Voxzogo, vosoritide, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Congenital, familial and genetic disorders, PIP number: P/0286/2024

Opinion/decision on a Paediatric investigation plan (PIP): Juluca, rilpivirine,dolutegravir, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: P/0283/2024

EMEA-001739-PIP02-16-M02

Opinion/decision on a Paediatric investigation plan (PIP): Tezspire, tezepelumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: P/0281/2024

Opinion/decision on a Paediatric investigation plan (PIP): Mysimba, bupropion hydrochloride,naltrexone hydrochloride, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Metabolism and nutrition disorders, PIP number: P/0280/2024

EMEA-001290-PIP01-12-M01

Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, Online, from 13 May 2025, 09:30 (CEST) to 13 May 2025, 13:00 (CEST)

Meeting summary of the Medicine Shortages SPOC Working Party meeting on 13 May 2025

Opinion/decision on a Paediatric investigation plan (PIP): Fasenra, Benralizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: P/0307/2024

Opinion/decision on a Paediatric investigation plan (PIP): Rydapt, Midostaurin, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps), PIP number: P/0305/2024